Amphiregulin as a biomarker for monitoring life-threatening acute graft-versus-host disease: secondary analysis of two prospective clinical trials

Authors

Shernan G. Holtan, Najla El Jurdi, Armin Rashidi, Brian C. Betts, Connor Demorest, John P. Galvin, Margaret L. MacMillan, Daniel J. Weisdorf, Angela Panoskaltsis-Mortari and Michael A. Pratta

1University of Minnesota, Adult Blood and Marrow Transplant & Cell Therapy Program, Minneapolis, MN; 2Fred Hutchinson Cancer Center, Seattle, WA; 3Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; 4Incyte Corporation, Wilmington, DE and 5University of Minnesota, Pediatric Blood and Marrow Transplant & Cell Therapy Program, Minneapolis, MN, USA

Correspondence:
S. HOLTAN - sgholtan@umn.edu

https://doi.org/10.3324/haematol.2023.283215

Received: April 17, 2023.
Accepted: September 5, 2023.
Early view: September 14, 2023.

©2024 Ferrata Storti Foundation
Published under a CC BY-NC license

Data-sharing statement
Reasonable requests for data may be sent to the author for correspondence (SGH).
SUPPLEMENTAL FIGURES

**Supplemental Figure 1**

A. Correlation of AREG Samples (N=47) ELISA vs ProteinSimple Ella
   \[ r=0.8656, p=0.0001 \]

B. UMN (uhCG/EGF) AREG Cutoff of 330 pg/ml
   Median survival not reached vs 177 days, \( p=0.016 \)

C. REACH1 (ruxolitinib) AREG Cutoff of 330 pg/ml
   Median survival not reached vs 74 days, \( p=0.005 \)

**Supplemental Figure 2**

UMN (uhCG/EGF) UREG vs Study Visit

REACH1 (ruxolitinib) UREG vs Study Visit